Form 4: Director Gerhard Burbach Receives Sight Sciences RSU Grant

Director Gerhard Burbach was granted 28,261 restricted stock units as part of the Sight Sciences non-employee director compensation program.

Summary

• Director Gerhard Burbach received a grant of 28,261 restricted stock units (RSUs) on June 4, 2026.
• The grant is valued at approximately $130,000 based on the closing price on the grant date.
• The RSUs are scheduled to vest on the earlier of June 4, 2027, or the date of the 2027 annual meeting of stockholders.
• Vesting is contingent upon the director's continued service on the board.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standardized compensation practice under the established Non-Employee Director Compensation Program.

Negatives

• The grant results in minor dilution to existing shareholders upon vesting.

Risks

• Vesting is subject to the director's continued service, creating a dependency on board retention.

Future Outlook

The RSUs will vest in one year, provided the director remains in service, increasing the director's direct equity stake in the company.

Industry Context

StockSavvy.ai notes that equity-based compensation for non-employee directors is a standard corporate governance practice in the medical device and biotechnology sectors to ensure long-term alignment with shareholder value.

Comparison to Industry Standards

• The grant size and structure are consistent with typical director compensation packages for mid-cap medical technology companies.
• One-year cliff vesting is a standard industry practice for annual director equity awards.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution impact.
• Director: Increased equity stake in the company.

Next Steps

• Vesting of the RSU grant on June 4, 2027, or the 2027 annual meeting date.

Key Dates

Keywords

Sight Sciences, SGHT, Form 4, Director Compensation, Restricted Stock Units, Insider Transaction